Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Sales (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Return on Sales for 9 consecutive years, with 565.27% as the latest value for Q1 2023.

  • On a quarterly basis, Return on Sales rose 4633.0% to 565.27% in Q1 2023 year-over-year; TTM through Mar 2023 was 565.27%, a 4633.0% increase, with the full-year FY2025 number at 14.2%, changed N/A from a year prior.
  • Return on Sales was 565.27% for Q1 2023 at Crescent Biopharma, up from 622.52% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.85% in Q1 2020 to a low of 101403.25% in Q2 2021.
  • A 4-year average of 8098.21% and a median of 200.23% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: plummeted -10139991bps in 2021, then surged 10122635bps in 2022.
  • Crescent Biopharma's Return on Sales stood at 95.51% in 2020, then crashed by -935bps to 988.47% in 2021, then soared by 37bps to 622.52% in 2022, then increased by 9bps to 565.27% in 2023.
  • Per Business Quant, the three most recent readings for CBIO's Return on Sales are 565.27% (Q1 2023), 622.52% (Q4 2022), and 581.55% (Q3 2022).